KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Total Non-Current Liabilities (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $216.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 7.65% to $216.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $216.0 million through Dec 2025, down 7.65% year-over-year, with the annual reading at $216.0 million for FY2025, 7.65% down from the prior year.
  • Total Non-Current Liabilities hit $216.0 million in Q4 2025 for Vir Biotechnology, up from $210.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $878.4 million in Q1 2022 to a low of $210.0 million in Q3 2025.
  • Historically, Total Non-Current Liabilities has averaged $397.7 million across 5 years, with a median of $314.8 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 481.15% in 2021 and later plummeted 66.17% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $519.9 million in 2021, then soared by 37.15% to $713.0 million in 2022, then plummeted by 56.1% to $313.0 million in 2023, then dropped by 25.3% to $233.9 million in 2024, then decreased by 7.65% to $216.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for VIR at $216.0 million in Q4 2025, $210.0 million in Q3 2025, and $232.0 million in Q2 2025.